A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants with Opioid Use Disorder and High-risk Opioid Use
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine; Buprenorphine; Buprenorphine
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Sponsors Indivior
Most Recent Events
- 19 Nov 2024 According to Indivior PLC Media Release, data from the study were presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference in Hamilton, Ontario, Canada.
- 19 Nov 2024 Results presented in the Indivior PLC Media Release.
- 01 Jul 2024 Status changed from active, no longer recruiting to completed.